Samrat Pharmachem [SAMRATPH] vs Ghcl [GHCL] Detailed Stock Comparison

Samrat Pharmachem Ltd.

BSE
Loading...

Ghcl Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Samrat Pharmachem Ltd. wins in 4 metrics, Ghcl Ltd. wins in 15 metrics, with 0 ties. Ghcl Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Samrat Pharmachem Ltd. Ghcl Ltd. Better
P/E Ratio (TTM) 39.68 9.54 Ghcl Ltd.
Price-to-Book Ratio 0.98 1.33 Samrat Pharmachem Ltd.
Debt-to-Equity Ratio 15.49 2.66 Ghcl Ltd.
PEG Ratio -0.34 -0.31 Ghcl Ltd.
EV/EBITDA -93.75 5.10 Ghcl Ltd.
Profit Margin (TTM) -0.58% 16.60% Ghcl Ltd.
Operating Margin (TTM) -1.33% 17.17% Ghcl Ltd.
EBITDA Margin (TTM) N/A 17.17% N/A
Return on Equity 9.91% 17.89% Ghcl Ltd.
Return on Assets (TTM) 5.85% 14.91% Ghcl Ltd.
Free Cash Flow (TTM) $-105.99M $3.23B Ghcl Ltd.
Dividend Yield 0.29% 1.97% Ghcl Ltd.
1-Year Return -41.18% -31.42% Ghcl Ltd.
Price-to-Sales Ratio (TTM) 0.24 1.53 Samrat Pharmachem Ltd.
Enterprise Value $597.84M $37.40B Ghcl Ltd.
EV/Revenue Ratio 0.21 1.22 Samrat Pharmachem Ltd.
Gross Profit Margin (TTM) 2.59% 42.51% Ghcl Ltd.
Revenue per Share (TTM) $936 $321 Samrat Pharmachem Ltd.
Earnings per Share (Diluted) $-5.42 $53.16 Ghcl Ltd.
Beta (Stock Volatility) -0.35 -0.42 Ghcl Ltd.

Samrat Pharmachem Ltd. vs Ghcl Ltd. Stock Performance Analysis

Loading Price Chart...

SAMRATPH
GHCL

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Samrat Pharmachem Ltd.0.55%-1.82%-3.65%-2.01%-20.44%-11.37%
Ghcl Ltd.3.58%3.98%-5.67%-1.96%-22.53%-20.64%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Samrat Pharmachem Ltd.-41.18%-54.10%-17.42%588.68%951.05%2,351.16%
Ghcl Ltd.-31.42%-14.38%50.01%155.92%1,015.16%297.46%

Performance & Financial Health Analysis: Samrat Pharmachem Ltd. vs Ghcl Ltd.

MetricSAMRATPHGHCL
Market Information
Market Cap i₹676.34M₹46.18B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,760120,135
90 Day Avg. Volume i2,391157,777
Last Close₹201.85₹445.85
52 Week Range₹190.00 - ₹389.00₹416.60 - ₹667.20
% from 52W High-48.11%-33.18%
All-Time High₹1,250.00 (Sep 19, 2022)₹779.00 (Jan 27, 2025)
% from All-Time High-83.85%-42.77%
Growth Metrics
Quarterly Revenue Growth0.00%-0.03%
Quarterly Earnings Growth0.00%-0.37%
Financial Health
Profit Margin (TTM) i-0.01%0.17%
Operating Margin (TTM) i-0.01%0.17%
Return on Equity (TTM) i0.10%0.18%
Debt to Equity (MRQ) i15.492.66
Cash & Liquidity
Book Value per Share (MRQ)₹228.64₹380.30
Cash per Share (MRQ)₹62.79₹119.25
Operating Cash Flow (TTM) i₹1.26M₹8.25B
Levered Free Cash Flow (TTM) i₹71.12M₹6.24B
Dividends
Last 12-Month Dividend Yield i0.29%1.97%
Last 12-Month Dividend i₹1.00₹12.00

Valuation & Enterprise Metrics Analysis: Samrat Pharmachem Ltd. vs Ghcl Ltd.

MetricSAMRATPH (Apr 24, 2026)GHCL (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i39.689.54
Forward P/E iN/A7.70
PEG Ratio i-0.34-0.31
Price to Sales (TTM) i0.241.53
Price to Book (MRQ) i0.981.33
Market Capitalization
Market Capitalization i₹676.34M₹46.18B
Enterprise Value i₹597.84M₹37.40B
Enterprise Value Metrics
Enterprise to Revenue i0.211.22
Enterprise to EBITDA i-93.755.10
Risk & Other Metrics
Beta i-0.35-0.42
Book Value per Share (MRQ) i₹228.64₹380.30

Financial Statements Comparison: Samrat Pharmachem Ltd. vs Ghcl Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSAMRATPH (2025)GHCL (2025)
Revenue/Sales i2.86B31.76B
Cost of Goods Sold i2.71B17.58B
COGS % of Revenue i94.7%55.3%
Gross Profit i152.75M14.18B
Gross Margin i5.3%44.7%
Research & Development i0N/A
Operating Income (EBIT) i97.54M7.68B
Operating Margin i3.4%24.2%
EBITDA i107.17M9.20B
EBITDA Margin i3.7%29.0%
Pre-Tax Income i98.86M8.36B
Pre-Tax Income % of Revenue i3.5%26.3%
Income Tax i27.74M2.12B
Income Tax % of Revenue i1.0%6.7%
Net Income (Profit) i71.12M6.24B
Profit Margin i2.5%19.6%

Balance Sheet & Liquidity Metrics

MetricSAMRATPH (2025)GHCL (2025)
Cash & Equivalents i483,000986.30M
Total Current Assets i1.03B19.54B
Total Current Assets % of Revenue i36.2%61.5%
Total Current Liabilities i495.83M3.68B
Total Current Liabilities % of Revenue i17.3%11.6%
Long-Term Debt i0805.80M
Long-Term Debt % of Revenue i0.0%2.5%
Total Shareholders Equity i718.00M34.89B
Retained Earnings i687.11M33.16B
Retained Earnings % of Revenue i24.0%104.4%
Property, Plant & Equipment i0989.00M

Cash Flow Statement Comparison

MetricSAMRATPH (2025)GHCL (2025)
Operating Cash Flow i1.26M8.25B
Operating Cash Flow % of Revenue i0.0%26.0%
Capital Expenditures i-5.07M-3.02B
Free Cash Flow i-105.99M3.23B
FCF Margin i-3.7%10.2%
Debt Repayment iN/A-994.30M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSAMRATPHGHCL
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i3.09M91.93M
Float Shares i1.19M63.12M
% Held by Insiders i59.26%39.72%
% Held by Institutions i0.00%21.54%
% Held by Public i40.74%38.74%

Dividend Analysis & Yield Comparison: Samrat Pharmachem Ltd. vs Ghcl Ltd.

MetricSAMRATPHGHCL
Last 12-Month Dividend i₹1.00₹12.00
Last 12-Month Dividend Yield i0.29%1.97%
3-Year Avg Annual Dividend i₹1.67₹13.83
3-Year Avg Dividend Yield i0.17%2.50%
3-Year Total Dividends i₹5.00₹41.50
Ex-Dividend DateSep 19, 2024Jul 17, 2025